<p>This week on The Genetics Podcast, Patrick is joined by Dr. John Lepore, physician-scientist and CEO of ProFound Therapeutics. They discuss ProFound Tx’s mission to expand the proteome to identify novel drug targets – which resulted in the ProFoundry atlas – and the ways in which John’s diverse experiences inform his approach as a leader.</p><p><br></p><p><strong>Show Notes: </strong></p><p><strong>0:00 </strong>Intro to The Genetics Podcast</p><p><strong>00:59</strong> Welcome to John</p><p><strong>02:01</strong> John’s background at GSK and his transition to drug discovery</p><p><strong>05:45</strong> Establishing ProFound Therapeutics to expand the proteome and identify novel drug targets </p><p><strong>08:27 </strong>Genomic origins of newly-identified proteins and the process of finding them</p><p><strong>09:49 </strong>Developing the ProFoundry atlas and integrating data across assays </p><p><strong>15:27</strong> Different approaches to inferring protein links and association to disease</p><p><strong>17:13 </strong>Collaboration with Pfizer to find regulators in the context of obesity</p><p><strong>18:04 </strong>Developing novel antibody-drug conjugates for cancer treatment</p><p><strong>20:27 </strong>Clarifying causality in proteomic data</p><p><strong>21:59 </strong>Approaching novel targets while considering industrial and business factors</p><p><strong>25:19 </strong>John’s background as a cardiologist and how that impacts his current work</p><p><strong>27:26 </strong>Tips for biotech companies looking to be noticed by pharma for collaborations</p><p><strong>30:30 </strong>Considerations for investigating new and different therapeutic modalities and techniques</p><p><strong>33:39 </strong>How John consistently reinforces the translational angle as a business leader</p><p><strong>36:24</strong> Closing remarks and future direction for ProFound Therapeutics</p><p><br></p><p><strong>Find out more</strong></p><ul><li><p>ProFound Therapeutics (<a href="https://www.profoundtx.com/"><u>https://www.profoundtx.com/</u></a>)</p></li></ul><p>Please consider rating and reviewing us on your chosen podcast listening platform! </p><p><a href="https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link"><u>https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link</u></a><br></p>

The Genetics Podcast

Sano Genetics

EP 178: Expanding the human proteome to facilitate drug discovery with John Lepore of ProFound Therapeutics

MAR 13, 202539 MIN
The Genetics Podcast

EP 178: Expanding the human proteome to facilitate drug discovery with John Lepore of ProFound Therapeutics

MAR 13, 202539 MIN

Description

<p>This week on The Genetics Podcast, Patrick is joined by Dr. John Lepore, physician-scientist and CEO of ProFound Therapeutics. They discuss ProFound Tx’s mission to expand the proteome to identify novel drug targets – which resulted in the ProFoundry atlas – and the ways in which John’s diverse experiences inform his approach as a leader.</p><p><br></p><p><strong>Show Notes: </strong></p><p><strong>0:00 </strong>Intro to The Genetics Podcast</p><p><strong>00:59</strong> Welcome to John</p><p><strong>02:01</strong> John’s background at GSK and his transition to drug discovery</p><p><strong>05:45</strong> Establishing ProFound Therapeutics to expand the proteome and identify novel drug targets </p><p><strong>08:27 </strong>Genomic origins of newly-identified proteins and the process of finding them</p><p><strong>09:49 </strong>Developing the ProFoundry atlas and integrating data across assays </p><p><strong>15:27</strong> Different approaches to inferring protein links and association to disease</p><p><strong>17:13 </strong>Collaboration with Pfizer to find regulators in the context of obesity</p><p><strong>18:04 </strong>Developing novel antibody-drug conjugates for cancer treatment</p><p><strong>20:27 </strong>Clarifying causality in proteomic data</p><p><strong>21:59 </strong>Approaching novel targets while considering industrial and business factors</p><p><strong>25:19 </strong>John’s background as a cardiologist and how that impacts his current work</p><p><strong>27:26 </strong>Tips for biotech companies looking to be noticed by pharma for collaborations</p><p><strong>30:30 </strong>Considerations for investigating new and different therapeutic modalities and techniques</p><p><strong>33:39 </strong>How John consistently reinforces the translational angle as a business leader</p><p><strong>36:24</strong> Closing remarks and future direction for ProFound Therapeutics</p><p><br></p><p><strong>Find out more</strong></p><ul><li><p>ProFound Therapeutics (<a href="https://www.profoundtx.com/"><u>https://www.profoundtx.com/</u></a>)</p></li></ul><p>Please consider rating and reviewing us on your chosen podcast listening platform! </p><p><a href="https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link"><u>https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link</u></a><br></p>